Page 9 - Human Umbilical Cord Mesenchymal Stem Cells

MSCs transplantation for osteoarthritis treatment

Fig 5. Forest plots of MD with 95% CI in Lequesne between patients undergoing MSC therapy and controls at 12 months. Fixed-
effects models were used.
https://doi.org/10.1371/journal.pone.0175449.g005

technologies [2,37,38]. In fact, all of the currently accepted treatments are aimed at symp-
tom control, rather than disease prevention [4,5]. MSCs are positive for the stromal cell
markers CD13, CD29, CD73, CD90, and CD105 and negative for the hematopoietic mark-
ers CD31, CD34, CD45, and HLA-DR [2,39]. MSCs can inhibit the proliferation of

Fig 6. Forest plots of MD with 95% CI in Lysholm between patients undergoing MSC therapy and controls at: (1) 6 months, (2) 12
months, and (3) 24 months. Random-effects models were used.
https://doi.org/10.1371/journal.pone.0175449.g006

PLOS ONE | https://doi.org/10.1371/journal.pone.0175449 April 27, 2017 9 / 16